Last reviewed · How we verify
NCT03778918
The Comparison Between the Biomarkers in Inflammatory Bowel Disease Patients and General Control Group
trial testing inflammatory bowel disease in Inflammatory Bowel Diseases in 200 participants. Status unknown.
30 June 2020
Quick facts
| Lead sponsor | Bo-In Lee |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 August 2016 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- inflammatory bowel disease
- IBS or Normal Control
Conditions studied
- Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
- Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Sponsor
Bo-In Lee — full company profile →
Who can join
Adults 19 to 75, any sex, with Inflammatory Bowel Diseases or Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. For this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, Crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. Selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. Males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. The outcome is a find of a blood-based biomarker that best reflects a disease activity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
REG/Reg family proteins: mediating gut microbiota homeostasis and implications in digestive diseases.
Qi Z, Pang W, Zha X, Liu Y, et al · · 2025 · cited 1× · PMID 41088844 · DOI 10.1080/19490976.2025.2568055
Verify or expand the search:
- PubMed search for NCT03778918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Bowel Diseases
Currently open trials in the same condition.
- NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
- NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
- NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03778918 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bo-In Lee
- Last refreshed: 3 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03778918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing